| Description | Obicetrapib (AMG-899) is an inhibitor of cholesteryl ester transfer protein. |
| Synonyms | TA8995, AMG899, Obicetrapib (free base), AMG 899, AMG-899, Obicetrapib, TA-8995 |
| molecular weight | 722.6 |
| Molecular formula | C32H31F9N4O5 |
| CAS | 866399-87-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 7.22 mg/mL (10 mM), Sonication is recommended. |
| References | 1. Filippatos TD, et al. Cholesteryl ester transfer protein inhibitors: challenges and perspectives. Expert Rev Cardiovasc Ther. 2016 Aug;14(8):953-62. 2. Amgen bulks out cardio package. Nat Biotechnol. 2015 Nov;33(11):1118. doi: 10.1038/nbt1115-1118a. 3. Mearns BM. Dyslipidaemia: Promising results for TA-8995 in TULIP. Nat Rev Cardiol. 2015 Aug;12(8):443. 4. Hovingh GK, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2015 Aug 1;386(9992):452-60. |